Treatment of hepatocellular carcinoma according to multiparametric therapeutic hierarchy approach: a prospective multicenter validation study
L. Canova,M. Iavarone,E. Alimenti,B. Antonelli,A.M. Ierardi,S. Crespi,M. Viganò,G. Cabibbo,A. Vitale,A. Sangiovanni,P. Lampertico
DOI: https://doi.org/10.1016/j.dld.2024.01.140
IF: 5.165
2024-02-01
Digestive and Liver Disease
Abstract:Background and aim Treatment strategy of hepatocellular carcinoma (HCC) is a complex decision-making process that should consider several variables in clinical practice. Recently, a “multiparametric therapeutic approach” has been proposed (Vitale A, Cabibbo G et al Lancet Oncol 2023). In this approach, the feasibility of all treatments is evaluated systematically in a hierarchical order, to match each patient with the optimal therapy. The aim of the study is to validate the reliability of the new multi-parametric decisional framework (MPDF) and the impact of the different variables included in the framework on the final treatment decision in clinical practice. Methods This is a prospective ongoing study with a first monocentric phase (A) and a second multicentric validation phase (B). Primary endpoints are: 1) adherence to MPDF for treatment allocation and 2) identification of the relative weight of variables involved in this multiparametric evaluation to predict treatment decision, while secondary endpoints are overall survival (OS) and radiological response after treatment. The study includes all consecutive patients with HCC managed in each center from September 1st, 2023. The disease is staged according to Barcelona Clinic Liver Cancer (BCLC) classification, while patient's characterization is conducted by Charlson Comorbidity Index (CCI), modified CCI (mCCI), Liver Frailty Index (LFI), Child-Pugh (CPT) and ALBI scores, MELD and skeletal muscle mass index (SMI) by CT-evaluation. Each patient is allocated to treatment according to MPDF, BCLC 2022 was used as benchmark of treatment allocation. Results As of November 1st, 2023, 48 patients were recruited into phase A of the study [median age 70 (52-87) years, 81% male, 37% HCV-Ab positive, 27% first diagnosis/treatment of HCC]. Thirteen (27%) patients were classified as BCLC 0, 17 (35%) as BCLC A, 6 (12.5%) as BCLC B, 6 (12.5%) as BCLC C and 6 (12.5%) as BCLC D. The median CCI was 8 (4-13), the median LFI was 4.15 (2.99-4.81) which corresponds to a pre-frail condition. Thirty-nine (81%) patients were in CPT class A, 7 (15%) in B and 2 (4%) in C, while 32 (67%) were classified ALBI grade 1 and 16 (33%) ALBI grade 2, and finally the median MELD score was 8.5 (6-22). Forty-four (92%) patients received treatment through a multidisciplinary team (MDT). According to the MPDF, 9 (19%) patients were allocated to liver transplant, 5 (10%) to laparoscopic surgical resection, 10 (21%) to microwave thermal ablation (MWTA), 7 (15%) to transarterial treatments (4 TACE and 3 TARE), 3 (6%) to other locoregional therapies (2 MWTA+TACE and 1 electrochemotherapy), 6 (13%) to systemic treatment and 5 (10%) to palliative care only. In 4 cases, the MDT decided for follow-up at 3 months and subsequent reassessment. The reason why each therapy was excluded for each patient is shown in Table 1. The treatment allocation was coherent to the BCLC 2022 treatment allocation system in the 69.2% for BCLC 0, 82.4% for BCLC A, 83.3% for BCLC B, 66.7% for BCLC C and 100% for BCLC D. Conclusions Preliminary data of our ongoing prospective study suggest that personalized approach for HCC treatment by MPDF is feasible in clinical practice and might help ensuring a customized approach in a standardized framework. Updated data will be presented at the meeting.
gastroenterology & hepatology